Each flim tablet contains Entecavir 0.5mg
CENTAURUS (entecavir) is indicated for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease
Most common adverse reactions (<3%, all severity grades) are headache, fatigue, dizziness, and nausea.
trihydrate U.S.P. eq. to Esomeprazole.........20mg
trihydrate U.S.P. eq. to Esomeprazole......... 40mg
ESOMEGA is indicated for the treatment of Treatment of Gastroesophageal Reflux Disease (GERD), Symptomatic Gastroesophageal Reflux Disease, NSAID-Associated Gastric Ulcer, H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy, Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome, Prolonged treatment after I.V. induced prevention of rebleeding of peptic ulcers.
Central nervous system: Headache (2% to 11%), Irritability (infants: 55%), dizziness (<1%), vertigo, drowsiness (children: 2%; adults: <1%)
Dermatologic: Pruritus (<1%)
Endocrine & metabolic: Altered thyroid hormone levels (increased thyroxine: 01%), decreased serum potassium (51%), decreased serum sodium (01./0), decreased thyroid hormones (thyroxine: 51%), increased gastrin (01%), increased serum potassium (01%), increased serum sodium (01%), increased thyroid stimulating hormone level (01./0), increased uric acid (010/0)
Gastrointestinal: Flatulence (51%), diarrhea (2% to 4%), abdominal pain (1% to 6%), nausea (oral: 51% to 2%), vomiting (infants: 1% to ,5%; adults: <1%), xerostomia (,1°/0), constipation (oral: ,1%)
Hematologic &oncologic: Change in platelet count (,1%)
Hepatic: Increased serum alkaline phosphatase (010/0), increased serum ALT (010/0), increased serum AST (010/0) Renal: Increased serum creatinine (51./o)
Respiratory: Cough (<1%), tachypnea (infants: 1%)
Miscellaneous: Fever (<1./0)
Cardiovascular: Esophageal varices
Gastrointestinal: Barrett esophagus, duodenitis, esophageal stenosis, esophageal ulcer, esophagitis, gastritis, mucosal discoloration
Hematologic & oncologic: Benign polyp
Miscellaneous: Benign nodule.
trihydrate U.S.P. eq. to Esomeprazole.........20mg
trihydrate U.S.P. eq. to Esomeprazole......... 40mg
ESOMEGA is indicated for the treatment of Treatment of Gastroesophageal Reflux Disease (GERD), Symptomatic Gastroesophageal Reflux Disease, NSAID-Associated Gastric Ulcer, H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy, Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome, Prolonged treatment after I.V. induced prevention of rebleeding of peptic ulcers.
Central nervous system: Headache (2% to 11%), Irritability (infants: 55%), dizziness (<1%), vertigo, drowsiness (children: 2%; adults: <1%)
Dermatologic: Pruritus (<1%)
Endocrine & metabolic: Altered thyroid hormone levels (increased thyroxine: 01%), decreased serum potassium (51%), decreased serum sodium (01./0), decreased thyroid hormones (thyroxine: 51%), increased gastrin (01%), increased serum potassium (01%), increased serum sodium (01%), increased thyroid stimulating hormone level (01./0), increased uric acid (010/0)
Gastrointestinal: Flatulence (51%), diarrhea (2% to 4%), abdominal pain (1% to 6%), nausea (oral: 51% to 2%), vomiting (infants: 1% to ,5%; adults: <1%), xerostomia (,1°/0), constipation (oral: ,1%)
Hematologic &oncologic: Change in platelet count (,1%)
Hepatic: Increased serum alkaline phosphatase (010/0), increased serum ALT (010/0), increased serum AST (010/0) Renal: Increased serum creatinine (51./o)
Respiratory: Cough (<1%), tachypnea (infants: 1%)
Miscellaneous: Fever (<1./0)
Cardiovascular: Esophageal varices
Gastrointestinal: Barrett esophagus, duodenitis, esophageal stenosis, esophageal ulcer, esophagitis, gastritis, mucosal discoloration
Hematologic & oncologic: Benign polyp
Miscellaneous: Benign nodule.
Each film coated tablet contains: Rifaximin 200mg and 550mg respectively; inactive ingredients: Povidone; Crosscarmellose Sodium; Colloidal Anhydrous Silica; Magnesium Stearate; Talcum; Lactose; Microcrystalline Cellulose; Opadry Orange 200F230017 (Ifaxa 200mg); Opadry Brown 200F265003 (Ifaxa 550mg).
IFAXA 200 mg is indicated for the treatment of patients (>12 years of age) with travelers' diarrhea caused by noninvasive strains of Escherichia coli.
IFAXA 550 mg is indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients 18 years of age.
Cardiovascular: Peripheral edema (15%), Central nervous system: Dizziness (13%), fatigue (12%)
Hepatic: Ascites (11%). Gastrointestinal: Nausea (14%)
2% to 10%:
Cardiovascular: Chest pain (>2% to 5%), hypotension (>2% to 5%. Central nervous system: Headache (10%), depression (7%), fever (6%), amnesia (>2% to 5%), attention disturbance (>2% to 5%), confusion (>2% to 5%), hypoesthesia (>2% to 5%), pain (>2% to 5%), tremor. Dermatological: Pruritus (9%), rash (5%), cellulitis (>2% to 5%). Endocrine and metabolism: Hyper-/hypoglycemia (>2% to 5%), hyperkalemia (>2% to 5%), hyponatremia (>2% to 5%). Gastrointestinal: Abdominal pain (6% to 9%), anorexia (>2% to 5%), dehydration (>2% to 5%), esophageal varices (>2% to 5%), weight gain (>2% to 5%), xerostomia (>2% to 5%). Hematologic: Anemia (8%). Neuromuscular & skeletal: Muscle spasms (9%), arthralgia (6%), myalgia (>2% to 5%). Respiratory: Nasopharyngitis (7%), dyspnea (6%), epistaxis(>2% to
5%), pneumonia (>2% to 5%), rhinitis (>2% to 5%), upper respiratory tract infection (>2% to 5%). Miscellaneous: Influenza-like illness (>2% to 5%)
<2% (Limited to important or life-threatening): Abnormal dreams, allergic dermatitis, anaphylaxis, angioneurotic edema (including tongue and facial edema with dysphagia), CDAD, dysuria, exfoliative dermatitis, flushing, hematuria, hypersensitivity reactions, insomnia, lymphocytosis, monocytosis, motion sickness, neutropenia, polyuria, proteinuria, sunburn, tinnitus, urticaria.
Each film coated tablet contains: Rifaximin 200mg and 550mg respectively; inactive ingredients: Povidone; Crosscarmellose Sodium; Colloidal Anhydrous Silica; Magnesium Stearate; Talcum; Lactose; Microcrystalline Cellulose; Opadry Orange 200F230017 (Ifaxa 200mg); Opadry Brown 200F265003 (Ifaxa 550mg).
IFAXA 200 mg is indicated for the treatment of patients (>12 years of age) with travelers' diarrhea caused by noninvasive strains of Escherichia coli.
IFAXA 550 mg is indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients 18 years of age.
Cardiovascular: Peripheral edema (15%), Central nervous system: Dizziness (13%), fatigue (12%)
Hepatic: Ascites (11%). Gastrointestinal: Nausea (14%)
2% to 10%:
Cardiovascular: Chest pain (>2% to 5%), hypotension (>2% to 5%. Central nervous system: Headache (10%), depression (7%), fever (6%), amnesia (>2% to 5%), attention disturbance (>2% to 5%), confusion (>2% to 5%), hypoesthesia (>2% to 5%), pain (>2% to 5%), tremor. Dermatological: Pruritus (9%), rash (5%), cellulitis (>2% to 5%). Endocrine and metabolism: Hyper-/hypoglycemia (>2% to 5%), hyperkalemia (>2% to 5%), hyponatremia (>2% to 5%). Gastrointestinal: Abdominal pain (6% to 9%), anorexia (>2% to 5%), dehydration (>2% to 5%), esophageal varices (>2% to 5%), weight gain (>2% to 5%), xerostomia (>2% to 5%). Hematologic: Anemia (8%). Neuromuscular & skeletal: Muscle spasms (9%), arthralgia (6%), myalgia (>2% to 5%). Respiratory: Nasopharyngitis (7%), dyspnea (6%), epistaxis(>2% to
5%), pneumonia (>2% to 5%), rhinitis (>2% to 5%), upper respiratory tract infection (>2% to 5%). Miscellaneous: Influenza-like illness (>2% to 5%)
<2% (Limited to important or life-threatening): Abnormal dreams, allergic dermatitis, anaphylaxis, angioneurotic edema (including tongue and facial edema with dysphagia), CDAD, dysuria, exfoliative dermatitis, flushing, hematuria, hypersensitivity reactions, insomnia, lymphocytosis, monocytosis, motion sickness, neutropenia, polyuria, proteinuria, sunburn, tinnitus, urticaria.
Each film coated tablet contains: Itopride HC1 50mg; Inactive Ingredients: Colloidal Anhydrous Silica; Croscarmellose Sodium; Magnesium Stearate; Talcum; Lactose; Microcrystalline Cellulose; Opadry Orange 85G53561; Carnauba Wax
Dynetic tablets are indicated for the treatment of
The following adverse events have been reported in patients receiving Itopride hydrochloride.
Blood and lymphatic system disorders:- leukopenia and thrombocytopenia.
Immune system disorders Anaphylactoid reaction.
Endocrine disorders:- increased prolactin level and gynecomastia.
Nervous system disorders :- Dizziness, headache and tremor.
Gastrointestinal disorders:- Diarrhea, constipation, abdominal pain, increased saliva and nausea.
Hepato-biliary disorders:- jaundice.
Skin and subcutaneous tissue disorders:- Rash, redness and itching.
Investigations Increased AST (SGOT), increased ALT (SGPT), increased gamma-(GTP), increased alkaline phosphatase, and increased bilirubin.
Ondansetron Hydrochloride USP
Eq. to Ondansetron 4/8 mg
Excipients Q.S.
Ondansetron is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy.
Ondansetron is indicated for the prevention of post-operative nausea and vomiting (PONV).
Headache, Sensation of warmth or flushing, Constipation, Seizures, movement disorders (including extrapyramidal reactions such as dystonic reactions, oculogyric crisis and dyskinesia), Arrhythmias, chest pain with or without ST segment depression, bradycardia, Hypotension, Hiccups, Asymptomatic increases in liver function tests.
Ondansetron Hydrochloride USP
Eq. to Ondansetron 4/8 mg
Excipients Q.S.
Ondansetron is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy.
Ondansetron is indicated for the prevention of post-operative nausea and vomiting (PONV).
Headache, Sensation of warmth or flushing, Constipation, Seizures, movement disorders (including extrapyramidal reactions such as dystonic reactions, oculogyric crisis and dyskinesia), Arrhythmias, chest pain with or without ST segment depression, bradycardia, Hypotension, Hiccups, Asymptomatic increases in liver function tests.
Each uncoated Tablet contains domperidone maleate BP
e.q. to domperidone 10mg
Excipients q.s
Vomisun is indicated for the relief of the symptoms of nausea and vomiting.
Allergic reactions such as skin rash, itching, shortness of breath, wheezing and/or swollen face, irregular heartbeat abnormal muscle movements or posture. tremor (shaking), muscle stiffness or unusual eye movements.
Leaking of milky fluid from the breasts sore or painful breasts decreased sex drive weakness mild skin rash or hives
Domperidone may be associated with an increased risk of heart rhythm disorder and cardiac arrest.
This risk may be more m most over 60 years old or taking doses higher than 30 mg per day.